MX2017002796A - Tasimelteon para tratar el sindrome de smith-magenis. - Google Patents

Tasimelteon para tratar el sindrome de smith-magenis.

Info

Publication number
MX2017002796A
MX2017002796A MX2017002796A MX2017002796A MX2017002796A MX 2017002796 A MX2017002796 A MX 2017002796A MX 2017002796 A MX2017002796 A MX 2017002796A MX 2017002796 A MX2017002796 A MX 2017002796A MX 2017002796 A MX2017002796 A MX 2017002796A
Authority
MX
Mexico
Prior art keywords
tasimelteon
magenis syndrome
smith
treating
treating smith
Prior art date
Application number
MX2017002796A
Other languages
English (en)
Inventor
Mihael H Polymeropoulos
Lavedan Christian
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of MX2017002796A publication Critical patent/MX2017002796A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electric Connection Of Electric Components To Printed Circuits (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Processing Of Solid Wastes (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Coils Or Transformers For Communication (AREA)

Abstract

Las modalidades de la invención se refieren al tratamiento de alteraciones del sueño en individuos con el Síndrome de Smith - Magenis (SMS).
MX2017002796A 2014-09-02 2015-08-29 Tasimelteon para tratar el sindrome de smith-magenis. MX2017002796A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462044856P 2014-09-02 2014-09-02
US201562169635P 2015-06-02 2015-06-02
PCT/US2015/047610 WO2016036619A1 (en) 2014-09-02 2015-08-29 Tasimelteon for treating smith-magenis syndrome

Publications (1)

Publication Number Publication Date
MX2017002796A true MX2017002796A (es) 2017-06-09

Family

ID=54147267

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002796A MX2017002796A (es) 2014-09-02 2015-08-29 Tasimelteon para tratar el sindrome de smith-magenis.

Country Status (17)

Country Link
US (5) US10179119B2 (es)
EP (2) EP4137129A1 (es)
JP (3) JP6903571B2 (es)
KR (2) KR20240015729A (es)
CN (2) CN116098887A (es)
AU (2) AU2015312252B2 (es)
BR (1) BR112017003644A2 (es)
CA (2) CA3124872A1 (es)
DK (1) DK3188727T3 (es)
ES (1) ES2936833T3 (es)
FI (1) FI3188727T3 (es)
HR (1) HRP20230070T1 (es)
HU (1) HUE061051T2 (es)
MX (1) MX2017002796A (es)
PT (1) PT3188727T (es)
SI (1) SI3188727T1 (es)
WO (1) WO2016036619A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4137129A1 (en) * 2014-09-02 2023-02-22 Vanda Pharmaceuticals Inc. Tasimelteon for treating smith-magenis syndrome
KR20240007693A (ko) * 2018-03-04 2024-01-16 반다 파마슈티칼즈, 인코퍼레이티드. 타시멜테온을 이용한 질환의 치료
CN113365618A (zh) * 2018-09-12 2021-09-07 万带兰制药公司 改善睡眠或睡醒后表现
KR102650321B1 (ko) 2019-12-13 2024-03-21 반다 파마슈티칼즈, 인코퍼레이티드. 액체 타시멜테온 제형 및 이의 사용 방법
EP4206696A1 (en) 2020-08-27 2023-07-05 Yokowo Co., Ltd. Inspection device
JP2024531569A (ja) * 2021-09-14 2024-08-29 ヴァンダ ファーマシューティカルズ インコーポレイテッド 自閉スペクトラム症患者の睡眠困難の治療

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9713690B1 (pt) 1996-12-10 2009-08-11 agentes melatoninérgicos benzodioxola, benzofurano, diidrobenzofurano e benzodioxano.
US20050137247A1 (en) 2003-12-22 2005-06-23 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
US7754902B2 (en) 2006-05-18 2010-07-13 Vanda Pharmaceuticals, Inc. Ruthenium(II) catalysts for use in stereoselective cyclopropanations
PT2028937E (pt) 2006-05-22 2015-04-09 Vanda Pharmaceuticals Inc Tratamento por agonista de melatonina
US20080260837A1 (en) 2007-04-20 2008-10-23 Qpharma, L.L.C. Physically stable aqueous suspensions of active pharmaceuticals
KR100928515B1 (ko) 2008-04-02 2009-11-26 주식회사 동부하이텍 데이터 수신 장치
US20120136050A1 (en) 2009-07-16 2012-05-31 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
KR102411809B1 (ko) 2012-01-26 2022-06-22 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
CN102675268A (zh) * 2012-05-18 2012-09-19 济南志合医药科技有限公司 制备(1r,2r)-2-(2,3-二氢苯并呋喃-4-基)环丙甲胺的方法
US10376487B2 (en) * 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
EP4137129A1 (en) 2014-09-02 2023-02-22 Vanda Pharmaceuticals Inc. Tasimelteon for treating smith-magenis syndrome
KR102650321B1 (ko) * 2019-12-13 2024-03-21 반다 파마슈티칼즈, 인코퍼레이티드. 액체 타시멜테온 제형 및 이의 사용 방법

Also Published As

Publication number Publication date
CN106604726A (zh) 2017-04-26
US20240293355A1 (en) 2024-09-05
JP6903571B2 (ja) 2021-07-14
US20170239210A1 (en) 2017-08-24
KR20170048541A (ko) 2017-05-08
US11266622B2 (en) 2022-03-08
FI3188727T3 (fi) 2023-02-20
HRP20230070T1 (hr) 2023-03-17
JP2020143159A (ja) 2020-09-10
NZ765911A (en) 2023-08-25
CA2957588C (en) 2021-08-31
DK3188727T3 (da) 2023-02-06
US20200237712A1 (en) 2020-07-30
KR20240015729A (ko) 2024-02-05
HUE061051T2 (hu) 2023-05-28
CA3124872A1 (en) 2016-03-10
JP7252390B2 (ja) 2023-04-04
SI3188727T1 (sl) 2023-03-31
AU2015312252B2 (en) 2020-07-02
AU2015312252A1 (en) 2017-03-30
NZ729901A (en) 2020-09-25
CA2957588A1 (en) 2016-03-10
JP2017526693A (ja) 2017-09-14
JP7132277B2 (ja) 2022-09-06
JP2022078291A (ja) 2022-05-24
EP3188727A1 (en) 2017-07-12
AU2020239640B2 (en) 2020-11-05
BR112017003644A2 (pt) 2017-11-28
CN116098887A (zh) 2023-05-12
US10179119B2 (en) 2019-01-15
EP4137129A1 (en) 2023-02-22
US20220133681A1 (en) 2022-05-05
US20190105297A1 (en) 2019-04-11
AU2020239640A1 (en) 2020-10-15
WO2016036619A1 (en) 2016-03-10
US10653665B2 (en) 2020-05-19
PT3188727T (pt) 2023-01-30
ES2936833T3 (es) 2023-03-22
EP3188727B1 (en) 2022-11-09

Similar Documents

Publication Publication Date Title
PH12016501763A1 (en) Multispecific antibodies
MX2020014121A (es) Agonistas parciales del receptor de insulina.
GB2548873B (en) Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
NZ731467A (en) Anti-tim3 antibodies and methods of use
EP3200915A4 (en) Biochars and biochar treatment processes
DK3201148T3 (da) Sammensmeltet telluratglas med forarbejdningstemperaturer på 420ºC
MY176855A (en) Anti-jagged1 antibodies and methods of use
MX2017002796A (es) Tasimelteon para tratar el sindrome de smith-magenis.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
GB201401528D0 (en) Social matching and interaction
TR201901062T4 (tr) Modifiye meningokokal fhbp polipeptidleri.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
MX2017000142A (es) Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica.
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
PT3978074T (pt) Terlipressina para tratamento da síndrome hepatorrenal de tipo 1
MX2015017638A (es) Polioles que contienen tanino, su producción y su uso.
MY181685A (en) Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer
GB201505313D0 (en) Glass treatment
MX2017002277A (es) Anticuerpos que potencian el factor h y sus usos.
IL249152B (en) Botulinum toxin for use in the treatment of paratonia
MX2018004091A (es) Antagonistas de il-17c para el tratamiento y/o prevencion de dermatitis atopica.
MX2016009541A (es) Metodo para tratar vajilla.
NZ711523A (en) Use of sedoheptulose for prevention or treatment of inflammation
CY1119212T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης